Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2005-06-21
2009-06-23
Bernhardt, Emily (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S255020, C544S121000, C544S385000
Reexamination Certificate
active
07550462
ABSTRACT:
Compounds of formula (I)wherein R1is 2-indanyl, R2is 1-methylpropyl, R3is a group selected from 2,6-dimethyl-3-pyridyl or 4,6-dimethyl-3-pyridyl, R4represents methyl and R5represents hydrogen or methyl or, R4and R5together with the nitrogen atom to which they are attached represent morpholino and pharmaceutically acceptable derivatives thereof are described, as are processes for their preparation, pharmaceutical compositions containing them and their use in medicine, particularly their use as oxytocin antagonists.
REFERENCES:
patent: 4596819 (1986-06-01), Nicolaides et al.
patent: 5464788 (1995-11-01), Bock et al.
patent: 5817751 (1998-10-01), Szardenings et al.
patent: 2005/0148572 (2005-07-01), Borthwick et al.
patent: 2007/0149524 (2007-06-01), Liddle
patent: 2007/0185162 (2007-08-01), Borthwick et al.
patent: 2007/0208031 (2007-09-01), Borthwick et al.
patent: 3830096 (1990-03-01), None
patent: 2326639 (1998-12-01), None
patent: WO9937304 (1999-07-01), None
patent: WO9938844 (1999-08-01), None
patent: WO 99/47549 (1999-09-01), None
patent: WO 03/053443 (2003-07-01), None
patent: WO 2005/000311 (2005-01-01), None
patent: WO 2005/000840 (2005-01-01), None
patent: WO2006/067462 (2005-12-01), None
patent: 2006/000759 (2006-01-01), None
patent: WO 2006/000400 (2006-01-01), None
patent: WO 2006/000759 (2006-01-01), None
Wolff, Mandred E. Burger's Medicinal Chemistry, 5th Ed. Part 1, pp. 975-977 (1995).
Banker et al. “Modern Pharmaceutics”, 3rd Ed. p. 596 (1996).
Testa et al. Pure Appl. Chem. vol. 76, pp. 907-914 (2004).
Vippagunta et al Advanced Drug Delivery Reviews, vol. 48, pp. 3-26 (2001).
Akerlund, Prog. Brain Res. vol. 139, p. 359-65 (2002) (Abstract).
Tsatsaris et al. Drugs, vol. 64(4), p. 375-82 (2004 (Abstract).
Grigorash, et al.,Chem. Heterocycl. Compound, 13(12): 1280-1281 (1977).
Kolasa, et al.,J. Org. Chem., 55(6): 1711-1721 (1990).
Pettibone, et al.Drug Development Research, 30(3): 129-142 (1993).
V. Stella,Pro Drugs as Novel Drug Delivery Systems, Pro Drugs: An Overview and Definition: 1-115 (1975).
Wyatt, et al.Bioorganic & Med. Chem. Letters, 11(10): 1301-1305 (2001).
Borthwick Alan David
Hickey Deirdre Mary Bernadette
Liddle John
Mason Andrew McMurtrie
Bernhardt Emily
Dustman Wayne J.
Gimmi Edward R.
Glaxo Group Limited
Peng Tony W.
LandOfFree
Piperazinediones as oxytocin receptor antagonists does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Piperazinediones as oxytocin receptor antagonists, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Piperazinediones as oxytocin receptor antagonists will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4146611